Discussions with payers for JOURNAVX are positive, aiming for broad access with increasing coverage. U.S. and ex-U.S. growth in CF is expected, with strong contributions from ALYFTREK and JOURNAVX.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay